Malik Rajesh 4
4 · G1 Therapeutics, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Malik Rajesh
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-02-12$4.62/sh−28,600$132,143→ 169,938 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-12−28,600→ 0 totalExercise: $0.30Exp: 2025-02-27→ Common Stock (28,600 underlying) - Exercise/Conversion
Common Stock
2024-02-12$0.30/sh+28,600$8,580→ 198,538 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price represents the weighted average price with a low of $4.45 and a high of $4.75. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
- [F3]Represents (i) 75,463 shares of common stock; (ii) 2,750 restricted stock units ("RSUs") from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iv) 13,425 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024.
- [F4]All shares underlying this option have vested.